Covaxin s phase 1 trial result shows robust immune response, mild adverse events - india news hindustantimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hindustantimes.com Daily Mail and Mail on Sunday newspapers.
Covaxin: No serious adverse events found, Bharat Biotech Phase 1 result shows
A medic administers Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research, during the Phase- 3 trials at the People s Medical College in Bhopal
(PTI)Premium
Share Via
Read Full Story
India s first indigenous Covid-19 vaccine Covaxin, developed by Bharat Biotech in association with Indian Council of Medical research, was found to be well tolerated in all dose groups with no vaccine-related serious adverse events, stated the interim findings of phase 1 trial of Covaxin.
The data also states that first vaccination, local and systemic adverse events were predominantly mild/moderate in severity & resolved rapidly, without prescribed medication.
Covid-19 Vaccine In Telangana From Sankranthi Published by GulteDesk December 16, 2020
The Telangana government is gearing up to begin immunisation against Covid-19 from Sankranti, that falls in mid-January. The first dose of the vaccine will be administered for 80 lakh people in targeted groups in 8-10 days and the second dose in another four weeks, according to Telangana public health director G. Srinivas. Preparations are in full swing for the vaccination of all targeted and vulnerable groups in the state.
So far, the DCGI has not accorded formal emergency use authorisation to any vaccine but it is being said that Hyderabad-based Bharat Biotech’s Covaxin and Serum Institute of India’s Covishield are more suitable for Indian conditions.
Updated Dec 16, 2020 | 20:30 IST
The vaccine was well tolerated in all dose groups with no vaccine-related serious adverse events. The most common adverse event was pain at the injection site, which resolved spontaneously. Representational Image
Key Highlights
After the first vaccination, local and systemic adverse events were predominantly mild or moderate in severity and resolved rapidly, without any prescribed medication
The document states that vaccine induced neutralizing antibody
The interim findings of Phase 1 human trial of indigenous COVAXIN, developed by Hyderabad-based Bharat Biotech, suggests that the vaccine induces an immune response and registered no serious adverse events. The vaccine was well tolerated in all dose groups with no vaccine-related serious adverse events. The most common adverse event was pain at the injection site, which resolved spontaneously, a pre-print document accessed by Mirror Now read.
Covid-positive Haryana Minister Vij admitted to Medanta in critical condition
By IANS |
Published on
Wed, Dec 16 2020 0:06 IST |
22 Views
Haryana Sports Minister Anil Vij. (Image Source: IANS). Image Source: IANS
New Delhi, Dec 15 : Haryana Health Minister Anil Vij, who is currently battling the Covid-19 infection, was on Tuesday admitted to Gurugram s Medanta Hospital in a critical condition, officials said.
The minister is getting treatment under Dr Sushila Kataria, senior director of Internal Medicine Department at Medanta, sources told IANS, adding that the minister is suffering from lung infection.
However, there was no official response from the hospital.
Vij was admitted to Medanta in the evening from the Haryana government s Post-Graduate Institute of Medical Sciences (PGIMS) in Rohtak where he was admitted on Saturday and had received convalescent plasma therapy. The institute had stated that Vij had moderate Covid-19 with bilateral viral pneumon